Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT003 SAD and MAD in Healthy and Overweight/Obese Volunteers
NCT07184502Phase 1Recruiting
- Sponsor
- QL Biopharm
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZT003 in obesity (2 arms), sponsored by QL Biopharm. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at Day 36, Incidence of Serious Adverse Events at Day 36 and 13 more. Started Oct 2025; status: recruiting.
02
Drugs
ZT003
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07184502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184502.